Invivyd, Inc. - Common Stock IVVD 深 滬
等待開盤 10-06 09:30:00 美东时间
1.16
-0.060
-4.92%
華盛通- 最 高1.296
- 今 開1.16
- 成交量 200.58万股
- 最 低 1.145
- 昨 收 1.22
- 總市值 2.48亿
- 52周最高 2.74
- 市盈率 靜 --
- 換手率 0.94%
- 52周最低 0.3546
- 委 比 21.48%
- 總股本 2.14亿
- 歷史最高 78.82
- 量 比 0.92
- 振 幅 12.38%
- 歷史最低 0.3546
- 每 手 1
- 風險率 1.28%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Invivyd Appoints New Director Amid Nasdaq Compliance
Invivyd ( ($IVVD) ) has shared an update. On September 22, 2025, Invivyd, Inc. ...
09-25 16:59
Invivyd Appoints Paul B. Bolno, M.D. to Its Board of Directors
Invivyd, Inc. announced the appointment of Paul B. Bolno, M.D., as a Board member and Compensation Committee member. Dr. Bolno, President and CEO of Wave Life Sciences, brings extensive experience in advancing biotechnology pipelines. He will support Invivyd's efforts to develop innovative therapies for viral infectious diseases, starting with COVID-19 and potentially Long COVID. Invivyd, focused on protecting against serious viral diseases, rece...
09-24 20:01
Invivyd Announces Appointment of Kristie Kuhl as Chief Communications Officer
Invivyd, Inc. appoints Kristie Kuhl as Chief Communications Officer to lead communications and patient advocacy efforts. Kuhl, recognized for her expertise in health communications, will help build trust and support growth as Invivyd advances its mission to develop monoclonal antibodies for viral disease prevention and treatment. She emphasizes the importance of bold, clear communication in advancing the company's mission.
09-17 11:01
SPEAR Study Group to Present its Recommended Long COVID Antibody Study Design Featuring Invivyd’s VYD2311 At RECOVER-TLC Workshop September 9-10, 2025
SPEAR Study Group proposes a clinical study to evaluate monoclonal antibody VYD2311 for treating Long COVID, aiming to reduce circulating spike protein and explore clinical benefits. The study design involves maintaining high antiviral antibody levels to suppress chronic infection. Researchers Amy Proal and David Putrino will present the proposal to RECOVER-TLC. VYD2311 is expected to be a promising candidate for addressing persistent viral reser...
09-04 11:01
Steven Cohen's Biotech Bets Are Getting Bolder — And Smaller
Billionaire hedge fund manager Steven Cohen is diving into small-cap biotech with new stakes in two clinical-stage companies, signaling confidence in their potential for outsized returns.
08-30 00:42
Point72 Hedge-Fund Manager, Steve Cohen, Discloses 8% Passive Stake In Invivyd
-SEC Filing
08-28 04:58
美股牛股 | 回声星通信飙升70%，AT&T拟以230亿美元收购其频谱许可证；先科电子涨超15%
回声星通信飙升70%，AT&T拟以230亿美元收购其频谱许可证；CareCloud涨超15%，完成对Medsphere的收购；Q2净销售额创下纪录，先科电子涨超15%>>
08-27 15:48
Invivyd to Participate in Upcoming Investor Conferences
Invivyd, Inc. announced it will present at the Cantor Global Healthcare Conference 2025 on September 3, 2025, and the H.C. Wainwright 27th Annual Global Investment Conference on September 8, 2025. Both events will be held in New York, NY. Live webcasts will be available on the company's investor website, investors.invivyd.com, and archived for 30 days. The management team will also host investor meetings. Invivyd, a biopharmaceutical company focu...
08-27 11:01
Invivyd rallies amid interest in COVID therapy
Shares of microcap biotech Invivyd (NASDAQ:IVVD) jumped ~94% on Tuesday to reach the highest level in more than five months, a rally not seen since early this year as the company’s experimental COVID-...
08-27 02:41
